Analysts expect that LivaNova PLC (NASDAQ:LIVN – Get Rating) will report $247.73 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for LivaNova’s earnings. The lowest sales estimate is $245.30 million and the highest is $252.10 million. LivaNova posted sales of $264.50 million during the same quarter last year, which would indicate a negative year over year growth rate of 6.3%. The firm is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that LivaNova will report full-year sales of $1.02 billion for the current fiscal year, with estimates ranging from $1.01 billion to $1.03 billion. For the next fiscal year, analysts expect that the firm will post sales of $1.09 billion, with estimates ranging from $1.08 billion to $1.12 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for LivaNova.
LivaNova (NASDAQ:LIVN – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $0.48 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.48. LivaNova had a negative net margin of 9.69% and a positive return on equity of 9.57%. The company had revenue of $240.20 million during the quarter, compared to the consensus estimate of $231.57 million. During the same quarter in the previous year, the firm earned $0.35 earnings per share. The firm’s quarterly revenue was down 3.0% on a year-over-year basis.
LivaNova stock traded up $1.02 during trading on Tuesday, reaching $66.62. The stock had a trading volume of 305,016 shares, compared to its average volume of 347,131. LivaNova has a 52-week low of $58.18 and a 52-week high of $93.89. The business has a 50 day moving average price of $77.14 and a 200 day moving average price of $79.68. The company has a quick ratio of 2.26, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. The stock has a market cap of $3.56 billion, a PE ratio of -33.48 and a beta of 0.91.
In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Friday, February 25th. The shares were sold at an average price of $80.00, for a total value of $80,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Damien Mcdonald sold 2,784 shares of the company’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total transaction of $226,896.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,784 shares of company stock worth $470,316 over the last 90 days. Insiders own 0.37% of the company’s stock.
Large investors have recently modified their holdings of the business. Arizona State Retirement System grew its position in LivaNova by 7.6% in the fourth quarter. Arizona State Retirement System now owns 14,320 shares of the company’s stock valued at $1,252,000 after acquiring an additional 1,012 shares in the last quarter. Yousif Capital Management LLC acquired a new stake in LivaNova in the fourth quarter worth $2,415,000. Deutsche Bank AG increased its position in LivaNova by 5.5% in the third quarter. Deutsche Bank AG now owns 35,508 shares of the company’s stock worth $2,812,000 after buying an additional 1,840 shares during the period. Profund Advisors LLC increased its position in LivaNova by 5.9% in the fourth quarter. Profund Advisors LLC now owns 4,165 shares of the company’s stock worth $364,000 after buying an additional 232 shares during the period. Finally, Balyasny Asset Management LLC increased its holdings in shares of LivaNova by 34.6% during the third quarter. Balyasny Asset Management LLC now owns 654,894 shares of the company’s stock valued at $51,861,000 after purchasing an additional 168,427 shares during the period. 97.34% of the stock is owned by institutional investors.
LivaNova Company Profile (Get Rating)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.